China is currently the world’s second-largest market for pharmaceuticals behind the United States, and it continues to grow at a very strong pace. Pfizer is well-positioned to take advantage of this growth; China represents one of the company’s fastest-growing markets around the globe.

“Our business in China has done extremely well in recent years,” says John Sweetman, Pfizer’s treasury director for the Asia-Pacific (APAC) region. “We’re very excited about our growth prospects in future years as well.”

Many of the products Pfizer sells in China are manufactured in-country. However, the company’s Chinese business units import a significant volume of pharmaceutical ingredients and raw materials from Pfizer entities abroad, as well as some finished products for local distribution. In the past, these intercompany transactions, worth more than US$1 billion annually, were always settled in U.S. dollars (USD), which was the only viable option prior to the internationalization of the renminbi.

Complete your profile to continue reading and get FREE access to Treasury & Risk, part of your ALM digital membership.

Your access to unlimited Treasury & Risk content isn’t changing.
Once you are an ALM digital member, you’ll receive:

  • Critical Treasury & Risk information including in-depth analysis of treasury and finance best practices, case studies with corporate innovators, informative newsletters, educational webcasts and videos, and resources from industry leaders.
  • Exclusive discounts on ALM and Treasury & Risk events.
  • Access to other award-winning ALM websites including PropertyCasualty360.com and Law.com.

Already have an account?


NOT FOR REPRINT

© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.

Meg Waters

Meg Waters is the editor in chief of Treasury & Risk. She is the former editor in chief of BPM Magazine and the former managing editor of Business Finance.

More from this author

Treasury & Risk

Join Treasury & Risk

Don’t miss crucial treasury and finance news along with in-depth analysis and insights you need to make informed treasury decisions. Join Treasury & Risk now!

  • Free unlimited access to Treasury & Risk including case studies with corporate innovators, informative newsletters, educational webcasts, and resources from industry leaders.
  • Exclusive discounts on ALM and Treasury & Risk events.
  • Access to other award-winning ALM publications including PropertyCasualty360.com and Law.com.

Already have an account? Sign In Now
Join Treasury & Risk

Copyright © 2024 ALM Global, LLC. All Rights Reserved.